Search for: "Janssen Pharmaceutica Inc." Results 1 - 20 of 65
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
The court granted Teva’s motion, finding the facts analogous to the Federal Circuit’s decision in Janssen Pharmaceutica, N.V. v. [read post]
The court granted Teva’s motion, finding the facts analogous to the Federal Circuit’s decision in Janssen Pharmaceutica, N.V. v. [read post]
The court granted Teva’s motion, finding the facts analogous to the Federal Circuit’s decision in Janssen Pharmaceutica, N.V. v. [read post]
27 Oct 2021, 5:15 am by Dennis Crouch
Janssen Pharmaceutica, N.V., No. 21-202 (NHK-Fintiv rule for denying petitions; appealability of IPR petition denial); Apple Inc. v. [read post]
20 Sep 2021, 3:31 pm by Dennis Crouch
Janssen Pharmaceutica (appealing institution denials); Apple Inc. v. [read post]
2 Sep 2020, 1:45 pm by Tom Lamb
The Defendants named in a typical lawsuit filed on behalf of an Elmiron user who developed vision problems might be some combination of the following: JANSSEN PHARMACEUTICALS, INC., f/k/a Ortho-McNeil-Janssen Pharmaceuticals, Inc., f/k/a Janssen Pharmaceutica Inc. [read post]
21 Jun 2018, 10:33 am by James Innocent
It was first developed by Janssen Pharmaceutica around 1960 and approved for American medical use in 1968 as an injectable anesthetic called Sublimaze. [read post]
7 Nov 2013, 11:24 pm by Jon Gelman
”Add caption Starr, a former sales representative for Janssen Pharmaceutica, a wholly-owned subsidiary of drugmaker Johnson & Johnson, felt as if she was being encouraged and pressured to market Risperdal off-label. [read post]
26 Mar 2013, 7:17 am by Brian A. Comer
South Carolina Lawyers Weekly ran an article last week concerning Janssen Pharmaceutica's appeal of a $327 million penalty handed down by Judge Robert Couch in 2011. [read post]
13 Jun 2011, 4:30 am by Laura Simons
Earlier this month, the State of South Carolina was awarded $327 million in damages from drugmaker Janssen Pharmaceutica, Inc., a Johnson & Johnson subsidiary, under the state’s Unfair Trade Practices Act for deceptive marketing of its anti-psychotic drug, Risperdal. [read post]
2 May 2011, 4:30 am by Laura Simons
A Spartanburg, South Carolina judge is set to decide how much money Janssen Pharmaceutica, Inc., a Johnson & Johnson subsidiary, should pay the state for what the jury found to be deceptive marketing by the company of its antipsychotic drug Risperdal. [read post]